{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T13:14:59Z","timestamp":1778591699009,"version":"3.51.4"},"reference-count":16,"publisher":"Pleiades Publishing Ltd","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dokl Biochem Biophys"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1134\/s1607672925700279","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T19:19:14Z","timestamp":1774898354000},"page":"122-131","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Retention Rate, Effectiveness, and\u00a0Safety of\u00a0Netakimab in\u00a0the\u00a0Treatment of\u00a0Patients with\u00a0Ankylosing Spondylitis: Two-Year Results of\u00a0the\u00a0Real Word Evidence LIBRA Study"],"prefix":"10.1134","volume":"526","author":[{"given":"Sh. F.","family":"Erdes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V. I.","family":"Mazurov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I. Z.","family":"Gaidukova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O. N.","family":"Anoshenkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I. B.","family":"Vinogradova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu. Yu.","family":"Grabovetskaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Yu.","family":"Davidian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O. E.","family":"Epifanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. A.","family":"Kiryukhina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. V.","family":"Masneva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I. V.","family":"Menshikova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O. N.","family":"Mironenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. E.","family":"Nikulenkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. V.","family":"Povarova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. N.","family":"Polyatika","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. R.","family":"Samigullina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. E.","family":"Sizikov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I. N.","family":"Totrov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I. F.","family":"Umnova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. L.","family":"Chudinov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"137","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"7806_CR1","first-page":"474","volume":"55","author":"I.Z. Gaidukova","year":"2017","unstructured":"Gaidukova, I.Z., Rebrov, A.P., Lapshina, S.A., Otteva,\u00a0E.N., Dubinina, T.V., Badokin, V.V., et al., Use of nonsteroidal anti-inflammatory drugs and biological agents for the treatment of axial spondyloarthritides. Recommendations of the Spondyloarthritis Study Group of Experts, All-Russian Public Organization \u201cThe Association of Rheumatology of Russia\u201d, Nauchno-Prakt. Revmatol., 2017, vol. 55, no. 5, pp. 474\u2013484.","journal-title":"Nauchno-Prakt. Revmatol."},{"key":"7806_CR2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/ard-2022-223296","volume":"82","author":"S. Ramiro","year":"2023","unstructured":"Ramiro, S., Nikiphorou, E., Sepriano, A., Ortolan, A., Webers, C., Baraliakos, X., et al., ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update, Ann. Rheum. Dis., 2023, vol.\u00a082, no. 1, pp. 19\u201334.","journal-title":"Ann. Rheum. Dis."},{"key":"7806_CR3","doi-asserted-by":"publisher","first-page":"94","DOI":"10.14412\/1996-7012-2021-2-94-105","volume":"15","author":"S.F. Erdes","year":"2021","unstructured":"Erdes, S.F., Recent advances and prospects of axial spondyloarthritis\/ankylosing spondylitis treatment, Modern Rheumatol. J., 2021, vol. 15, no. 2, pp. 94\u2013105.","journal-title":"Modern Rheumatol. J."},{"key":"7806_CR4","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3899\/jrheum.201551","volume":"49","author":"H. Griffiths","year":"2022","unstructured":"Griffiths, H., Smith, T., Mack, C., Leadbetter, J., Butcher, B., Acar, M., et al., Persistence to biologic therapy among patients with ankylosing spondylitis: an observational study using the OPAL dataset, J. Rheumatol., 2022, vol. 49, no. 2, pp. 150\u2013156.","journal-title":"J. Rheumatol."},{"key":"7806_CR5","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1080\/09546634.2017.1395794","volume":"29","author":"G. Carretero","year":"2018","unstructured":"Carretero, G., Puig, L., Carrascosa, J.M., Ferr\u00e1ndiz, L., Ruiz-Villaverde, R., de la Cueva, P., et al.; from the Spanish Group of Psoriasis, Redefining the therapeutic objective in psoriatic patients candidates for biological therapy, J. Dermatol. Treat., 2018, vol. 29, no. 4, pp.\u00a0334\u2013346.","journal-title":"J. Dermatol. Treat."},{"key":"7806_CR6","first-page":"151","volume":"10","author":"M. Acar","year":"2018","unstructured":"Acar, M., Juneja, P., and Handel, M., Treatment persistence of subcutaneous TNF inhibitors among Australian patients with immune-mediated rheumatic disease (IMRD), Open Access Rheumatol. Res. Rev., 2018, vol. 10, pp. 151\u2013160.","journal-title":"Open Access Rheumatol. Res. Rev."},{"key":"7806_CR7","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13075-019-1908-9","volume":"21","author":"U. Lindstr\u00f6m","year":"2019","unstructured":"Lindstr\u00f6m, U., Olofsson, T., Wedr\u00e9n, S., Qirjazo, I., and Askling, J., Biological treatment of ankylosing spondylitis: A nationwide study of treatment trajectories on a patient level in clinical practice, Arthritis Res. Ther., 2019, vol. 21, no. 1, p. 128.","journal-title":"Arthritis Res. Ther."},{"key":"7806_CR8","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3899\/jrheum.170477","volume":"45","author":"I.D. Flouri","year":"2018","unstructured":"Flouri, I.D., Markatseli, T.E., Boki, K.A., Papadopoulos, I., Skopouli, F.N., Voulgari, P.V., et al., Comparative analysis and predictors of 10-year tumor necrosis factor inhibitors drug survival in patients with spondyloarthritis: First-year response predicts longterm drug persistence, J. Rheumatol., 2018, vol. 45, no. 6, pp.\u00a0785\u2013794.","journal-title":"J. Rheumatol."},{"key":"7806_CR9","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1590\/S1518-8787.2016050006265","volume":"50","author":"M.A. Machado","year":"2016","unstructured":"Machado, M.A., Moura, C.S., Ferr\u00e9, F., Bernatsky, S., Rahme, E., and Acurcio Fde, A., Treatment persistence in patients with rheumatoid arthritis and ankylosing spondylitis, Rev. Saude Publica, 2016, vol. 50, p.\u00a050.","journal-title":"Rev. Saude Publica"},{"key":"7806_CR10","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1007\/s10067-023-06760-z","volume":"42","author":"C. Weinstein","year":"2023","unstructured":"Weinstein, C., Meehan, A.G., Lin, J., Briscoe, S.D., and Govoni, M., Long-term golimumab persistence: Five-year treatment retention data pooled from pivotal phase III clinical trials in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, Clin. Rheumatol., 2023, vol. 42, no. 12, pp. 3397\u20133405.","journal-title":"Clin. Rheumatol."},{"key":"7806_CR11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.14412\/1996-7012-2024-1-35-46","volume":"18","author":"V.I. Mazurov","year":"2024","unstructured":"Mazurov, V.I., Erdes, Sh.F., Gaydukova, I.Z., Dubinina, T.V., Pristrom, A.M., Kunder, E.V., et al., Long-term efficacy and safety of netakimab in patients with active ankylosing spondylitis: Results of three years of use in the international multicentre, randomized, double-blind, phase III clinical trial BCD-085-5\/ASTERA, Modern Rheumatol. J., 2024, vol. 18, no. 1, pp. 35\u201346.","journal-title":"Modern Rheumatol. J."},{"key":"7806_CR12","first-page":"700","volume":"61","author":"Sh. Erdes","year":"2023","unstructured":"Erdes, Sh., Mazurov, V.I., Gaydukova, I.Z., Anoshenkova, O.N., Vinogradova, I.B., Grabovetskaya, Yu.Yu., et al., Real-world retention rate, effectiveness, and safety of netakimab in the treatment of patients with ankylosing spondylitis: First year results of the LIBRA post-registration safety study, Nauchno-Prakt. Revmatol., 2023, vol. 61, no. 6, pp. 700\u2013710.","journal-title":"Nauchno-Prakt. Revmatol."},{"key":"7806_CR13","unstructured":"Efleira, Drug \u2116=(005293)-(RG-RU), 2024. \nhttps:\/\/grls.rosminzdrav.ru\/InstrImg\/2024\/09\/ 30\/1509140\/29e54a2a-45f6-4a55-b39c-480d32901f41.pdf. Accessed January 12, 2025."},{"key":"7806_CR14","doi-asserted-by":"publisher","unstructured":"Pons, M., Georgiadis, S., \u00d8stergaard, M., Ahmadzay,\u00a0Z.F., Glintborg, B., Heberg, J., Christensen, S.N., Rasmussen, S., Loft, A.G., Castrej\u00f3n, I., S\u00e1nchez-Alonso, F., Iannone, F., Nordstr\u00f6m, D., Hokkanen,\u00a0\u00a0A.-M., Ciurea, A., Nissen, M.J., Z\u00e1vada, J., Pavelka, K., Rotar, Z., Pirkmajer, K.P., Michelsen, B., Mielnik, P., Bernardes, M., Khmelinskii, N., Laas, K., Vorobjov, S., Codreanu, C., Macfarlane, G.J., Jones,\u00a0G.T., Gudbjornsson, B., Palsson, O., Wallman, J.K., Van Der Horst-Bruinsma, I., Onen, F., Hetland, M.L., and \u00d8rnbjerg, L.M., Four-year secukinumab treatment outcomes in European real-world patients with axial spondyloarthritis and psoriatic arthritis, Joint Bone Spine, 2025, vol. 92, no. 3, p. 105824. https:\/\/doi.org\/10.1016\/j.jbspin.2024.105824","DOI":"10.1016\/j.jbspin.2024.105824"},{"key":"7806_CR15","first-page":"376","volume":"58","author":"V.I. Mazurov","year":"2020","unstructured":"Mazurov, V.I., Gaydukova, I.Z., Erdes, Sh., Dubinina, T.V., Pristrom, A.M., Kunder, E.V., et al., Efficacy and safety of netakimab, anti-IL-17A monoclonal antibody, in patients with ankylosing spondylitis. Results of phase III international, multicenter, randomized double-blind clinical trial BCD-085-5\/ASTERA, Nauchno-Prakt. Revmatol., 2020, vol. 58, no. 4, pp. 376\u2013386.","journal-title":"Nauchno-Prakt. Revmatol."},{"key":"7806_CR16","first-page":"718","volume":"41","author":"V.I. Mazurov","year":"2023","unstructured":"Mazurov, V.I., Dubinina, T.V., Erdes, S., Lapshina, S.A., Soroka, N.F., Kunder, E.V., et al., Response to netakimab in radiographic axial spondyloarthritis patients with different baseline C-reactive protein, sacroiliitis evaluated by MRI and peripheral joint involvement status: A post-hoc analysis of the ASTERA study, Clin. Exp. Rheumatol., 2023, vol. 41, no. 3, pp. 718\u2013726.","journal-title":"Clin. Exp. Rheumatol."}],"container-title":["Doklady Biochemistry and Biophysics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1134\/S1607672925700279.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1134\/S1607672925700279","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1134\/S1607672925700279.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T12:49:34Z","timestamp":1778590174000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1134\/S1607672925700279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["7806"],"URL":"https:\/\/doi.org\/10.1134\/s1607672925700279","relation":{},"ISSN":["1607-6729","1608-3091"],"issn-type":[{"value":"1607-6729","type":"print"},{"value":"1608-3091","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"15 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Independent Multidisciplinary Committee for Ethical Review of Clinical Trials (extract from protocol no. 08 dated April 24, 2020). The study was conducted in accordance with the Declaration of Helsinki and the national standard \u201cGood Clinical Practice.\u201d Before inclusion in the screening, patients signed informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"ETHICS APPROVAL AND CONSENT TO PARTICIPATE"}},{"value":"The authors of this work declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"CONFLICT OF INTEREST"}}]}}